HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies

Files in This Item:
Lupus27_225.pdf369.07 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/68460

Title: Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies
Other Titles: Statin effects for thrombosis in SLE with aPL
Authors: Watanabe, T.1 Browse this author
Oku, K.2 Browse this author
Amengual, O.3 Browse this author →KAKEN DB
Hisada, R.4 Browse this author
Ohmura, K.5 Browse this author
Nakagawa, I.6 Browse this author
Shida, H.7 Browse this author
Bohgaki, T.8 Browse this author
Horita, T.9 Browse this author →KAKEN DB
Yasuda, S.10 Browse this author →KAKEN DB
Atsumi, T.11 Browse this author →KAKEN DB
Authors(alt): Watanabe, Toshiyuki1
Oku, Kenji2
Amengual, Olga3
Hisada, Ryo4
Ohmura, Kazumasa5
Nakagawa, Ikuma6
Shida, Haruki7
Bohgaki, Toshiyuki8
Horita, Tetsuya9
Yasuda, Shinsuke10
Atsumi, Tatsuya11
Keywords: systemic lupus erythematosus
antiphospholipid antibodies
thrombosis
statins
Issue Date: Feb-2018
Publisher: SAGE Publications
Journal Title: Lupus
Volume: 27
Issue: 2
Start Page: 225
End Page: 234
Publisher DOI: 10.1177/0961203317716787
PMID: 28659045
Abstract: The objective of this study is to identify the effects of statins and risk factors for thrombosis in patients with new onset of systemic lupus erythematosus (SLE) with or without antiphospholipid antibodies (aPL). Consecutive patients with SLE without history of thrombotic events were retrospectively enrolled from April 1997 to February 2014. The development of first thrombosis and death caused by thrombosis were defined as the study endpoint. Risk and protective factors for developing thrombosis were analyzed. A total of 152 patients, 80 positive and 72 negative for aPL, were included. In aPL-positive patients, 15 developed arterial (n=6) and venous (n=9) thrombosis (median follow-up period 69 months). Cox's proportional hazards model showed that older age at SLE onset and IgG-anticardiolipin antibodies (aCL) were statistically significant risks for thrombosis. Statin therapy was identified as a statistically significant protective factor against thrombosis (hazard ratio 0.12, 95% confidence interval 0.01-0.98). In aPL-negative patients (median follow-up period 46 months), seven patients developed thrombosis (five arterial and two venous). No risk factors for thrombosis were found in this group. In aPL-positive patients with SLE, the late disease onset and the presence of IgG-aCL represented additional risk factors for thrombosis. Statin treatment appeared as a protective factor for thrombosis.
Rights: T Watanabe, K Oku, O Amengual, R Hisada, K Ohmura, I Nakagawa, H Shida, T Bohgaki, T Horita, S Yasuda, T Atsumi, Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies, Lupus, Vol 27, Issue 2, 225-234. Copyright © 2018 The Author(s). Reprinted by permission of SAGE Publications.
Type: article (author version)
URI: http://hdl.handle.net/2115/68460
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 渥美 達也

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University